ASH 2021 - Myelofibrosis

Myelofibrosis patients typically prepare for allo-SCT by suspending ruxolitinib therapy, which subsequently results in worsening disease manifestations. Continuation of ruxolitinib therapy in an off-label approach offers a safer option according to interim phase 2 data.

Myelofibrosis patients refractory to JAK inhibitor therapy typically have poor prognosis. Pelabresib demonstrates improvement in clinical outcomes while maintaining an acceptable safety profile in this patient subset.

Anemia is a common side effect in many patients with myelofibrosis on ruxolitinib therapy. Phase 2 clinical trial data demonstrate mitigation of anemia indices in this patient population by sotatercept.

Patients with myelofibrosis who are refractory to JAK inhibitors often lack safe and effective treatment options. Selinexor may slow disease progression by reducing growth of malignant myelofibrosis cells.

Ruxolitinib is an approved therapy for myelofibrosis but some patients experience serious side effects. Fedratinib is an effective therapeutic option for these patients without development of severe adverse events.